Sylvia Dobo
BioCryst Pharmaceuticals (United States)(US)
Publications by Year
Research Areas
Coagulation, Bradykinin, Polyphosphates, and Angioedema, Influenza Virus Research Studies, Urticaria and Related Conditions, Hepatitis B Virus Studies, PI3K/AKT/mTOR signaling in cancer
Most-Cited Works
- → BCX4430 – A broad-spectrum antiviral adenosine nucleoside analog under development for the treatment of Ebola virus disease(2016)171 cited
- → Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial(2020)158 cited
- → Oral Plasma Kallikrein Inhibitor for Prophylaxis in Hereditary Angioedema(2018)112 cited
- → Long‐term safety and effectiveness of berotralstat for hereditary angioedema: The open‐label APeX‐S study(2021)51 cited
- → Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: A phase 3 randomized trial(2020)45 cited
- → Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The OPuS‐2 study(2018)40 cited
- → Single dose Peramivir for the Treatment of Acute Seasonal Influenza: Integrated Analysis of Efficacy and Safety from Two Placebo-Controlled Trials(2014)26 cited
- → Prophylaxis of hereditary angioedema attacks: A randomized trial of oral plasma kallikrein inhibition with avoralstat(2016)26 cited
- → Compartment Syndrome in the Critically Injured following Massive Resuscitation(1995)19 cited
- → Pharmacokinetics and Safety of the Nucleoside Analog Antiviral Drug Galidesivir Administered to Healthy Adult Subjects(2022)15 cited